MagVenture has been selling transcranial magnetic stimulation devices and TMS coils since 1992. We strive to offer TMS professionals the best TMS equipment in the market.

1992:  First MagPro stimulator hits the market (sold under the Dantec brand).

2001: MagVenture introduces the cost-effective Static Cool concept, allowing TMS researchers to run protocols without changing coils in the middle of sessions.

2004: MagVenture takes coil cooling to a new level with the Dynamic Cool concept, allowing TMS researchers to perform consecutive rTMS treatments without coil change.

2007: MagVenture is officially established under its own name.

2010: Subsidiary MagVenture Inc. is established in the US.

2010: MagVenture launches a complete rTMS research system, including a coil for double-blinded placebo-trials.

2011: MagVenture is the first TMS provider to receive CE approval for its depression treatment system known as MagVita TMS Therapy, now named MagVenture TMS Therapy.

2011: Subsidiary MagVenture GmbH is established in Germany.

2013: Researchers can now perform rTMS inside an MRi scanner with the new Mri-B91 coil from MagVenture.The Cool B91 coil is for so-called interleaved TMS in an MRi Tesla scanner. 


2014: A new coil for stimulating rodents sees the light of day, providing a valuable tool for animal model research.

2014:  The MagPro R20 is released, a taylormade solution for smaller start-up practices.

2015: MagVenture receives FDA clearance for the treatment of major depressive disorder. 

2017: Sales Subsidiary MagVenture Ltd., located in Reading just outside London, is established in the UK.

2018:  MagVenture receives FDA clearance for a  3 minute TBS depression treatment. This TBS (Theta burst stimulation) protocol is based on the world’s largest Randomized Control Trial with TMS to date. The article was published in the Lancet[Blumberger et al, 2018, The Lancet].  

2018: Besides subsidiaries in the US, Germany and the United Kingdom, MagVenture is now also represented in 50+ countries. MagVenture also launches a new, dark blue logo: 

2019: MagVenture receives CE approval  for a  3 minute TBS depression treatment.

2019: Sales Subsidiary MagVenture Ltda., located in São Paulo, is established in Brazil:

 

2020: MagVenture receives FDA clearance for adjunct treatment of Obsessive-Compulsive Disorder (OCD) in adult patients. 

2021: MagVenture takes coil positioning to a whole new level with the introduction of the MagVenture Flow Arm

2021: MagVenture receives CE approval for Addiction and OCD in adult patients

• Addiction, more specifically treatment of Psychoactive Substance User Disorder (PSUD) in adult patients.
• OCD: Adjunct treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD)
• Furthermore,  MagVenture TMS Therapy^® can reduce the symptoms of comorbid anxiety in patients suffering from depression